预约演示
更新于：2025-05-07
Ramosetron Hydrochloride
盐酸雷莫司琼
更新于：2025-05-07
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H18ClN3O |
InChIKeyXIXYTCLDXQRHJO-RFVHGSKJSA-N |
CAS号132907-72-3 |
关联
86
项与 盐酸雷莫司琼 相关的临床试验CTRI/2024/09/073332
Study on comparison of prophylactic phenylephrine infusion versus intravenous ramosetron on hypotension during spinal anaesthesia for herniorhhaphy , hernioplasty : A Randomized controlled trial - NIL
NCT06166615
The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) Versus Psyllium (Agio®) for the Treatment of Fecal Incontinence: Multicenter Randomized Trial (SERAFI)
NCT05577845
Safety & Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) Versus Loperamide for the Treatment of Low Anterior Resection Syndrome (RALLARS): Multicenter Randomized Controlled Trial
100 项与 盐酸雷莫司琼 相关的临床结果
登录后查看更多信息
100 项与 盐酸雷莫司琼 相关的转化医学
登录后查看更多信息
100 项与 盐酸雷莫司琼 相关的专利（医药）
登录后查看更多信息
507
项与 盐酸雷莫司琼 相关的文献（医药）2025-04-25The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Treatment of Irritable Bowel Syndrome with Predominant Diarrhea
Review
作者: Kim, Min Cheol ; Park, Yehyun ; Lee, Hong Sub
Irritable bowel syndrome with predominant diarrhea (IBS-D) is a subtype of irritable bowel syndrome that causes frequent loose stools. Although the precise pathophysiology remains unclear, factors, such as gut microbiota imbalance, visceral hypersensitivity, intestinal permeability changes, and stress, play significant roles. Recent studies have suggested that dysbiosis is a key contributor to IBS-D pathogenesis, emphasizing the need for targeted therapeutic strategies. The treatment of IBS-D involves pharmacological and non-pharmacological approaches. Pharmacological treatments include antidiarrheal agents, such as loperamide, which reduce stool frequency but have limited effects on pain relief. Antispasmodics, such as octylonium bromide and hyoscine butylbromide, alleviate abdominal pain by modulating intestinal motility. Rifaximin, a non-absorbable antibiotic, has shown efficacy in symptom reduction by altering the gut microbiota. Selective serotonin receptor antagonists, such as ramosetron, have benefits in symptom control, particularly in male patients. In addition, low-dose tricyclic antidepressants help manage pain and stool irregularities by modulating the gut-brain interactions. Non-pharmacological strategies include dietary modifications, with the low-FODMAP diet showing potential benefits despite concerns about long-term nutritional adequacy. Psychological interventions, such as cognitive behavioral therapy and gut-directed hypnotherapy, are recommended for patients with persistent symptoms unresponsive to medication. Mild physical activities, such as yoga and walking, relieve symptoms by improving gut motility and reducing stress. Personalized treatment approaches are essential because IBS-D presents a wide spectrum of symptoms. Clinicians should tailor therapeutic plans based on individual patient characteristics, balancing the benefits and risks of each intervention to optimize symptom control and improve the quality of life.
2025-04-01Korean Journal of Pain
Physicochemical stability of mixtures of non-steroidal anti-inflammatory drugs such as ketorolac and diclofenac and antiemetics such as ondansetron and ramosetron: an in vitro study
Article
作者: Lee, Chung Hun
Background:
Drugs administered intravenously during the postoperative period can mix before entering the bloodstream. This study assessed the stability of mixtures of non-steroidal anti-inflammatory drugs (ketorolac and diclofenac) and antiemetics (ondansetron and ramosetron) to determine their suitability for concurrent administration.
Methods:
Ketorolac or diclofenac was combined with ondansetron or ramosetron at a 1:1 volume ratio. Each mixture was stored in a propylene syringe at 24°C for 2 hours. The mixtures were assessed visually, and the pH was measured. Additionally, the drug concentrations were determined using high-performance liquid chromatography (HPLC).
Results:
Mixtures of ketorolac or diclofenac and ramosetron showed no crystal formation or pH changes, and HPLC analysis confirmed that the drug concentrations remained stable. In contrast, mixtures of ketorolac or diclofenac and ondansetron exhibited the visible formation of 10-50 μm crystals under a microscope. However, there were no changes in the pH levels, and HPLC analysis indicated that the drug concentrations remained stable for both the mixtures.
Conclusions:
Mixtures of ketorolac or diclofenac and ramosetron demonstrated physical and chemical stability for up to 2 hours, indicating that their concurrent use is feasible. Conversely, mixtures of ketorolac or diclofenac and ondansetron should be avoided due to the formation of crystals, even though the concentration of each drug remained stable.
2025-03-14MEDICINE
Impact of basal infusion on postoperative nausea and vomiting in fentanyl-based intravenous patient-controlled analgesia: A randomized controlled trial
Article
作者: Jeon, Yeong-Gwan ; Kim, Sujin ; Song, Seung Woo ; Cho, Yun Hyung ; So, Jung Hyun ; Park, Ji-Hyoung
Background::
Fentanyl-based intravenous patient-controlled analgesia (IV PCA) is widely prescribed postoperatively. Basal infusion of fentanyl through IV PCA is associated with postoperative nausea and vomiting. However, the role of basal infusion in fentanyl-based IV PCA is not well-established.
Methods::
This parallel-group, randomized controlled trial was conducted at a tertiary university medical center in the Republic of Korea from September 2022 to April 2023. Patient inclusion criteria were: age 20 to 65 years, intraperitoneal laparoscopic gynecologic surgery, patient-controlled analgesia (PCA) request from the surgical department, and written informed consent for PCA. Patients were allocated to basal infusion (BAS group) and bolus-only (BOL group) groups in a 1:1 ratio.A sum of 100 mL of analgesic mixture containing fentanyl 18.5 µg/kg, nefopam 120 mg, and ramosetron 0.3 mg was mixed in PCA pumps of both groups. For BAS group, basal infusion rate, bolus volume, and lock-out interval were 2 mL/hour, 1 mL, and 15 minutes, respectively. BOL group received no basal infusion; bolus volume and lock-out interval were 1 mL and 6 minutes, respectively.The primary outcome was postoperative nausea, measured using a self-response questionnaire 24 hours after operation and expressed as a 100-mm visual analog scale score. We also determined frequency of postoperative vomiting, quality of postoperative recovery (using Korean version of 15-item Quality of Recovery [QoR-15K] scale), and overall patient satisfaction with anesthetic service.
Results::
A sum of 82 of the 88 patients enrolled were included. The visual analog scale score for postoperative nausea was 31.4 ± 31.3 mm; the condition was more severe in the BAS group than in the BOL group (95% confidence interval of difference: 2.1–28.9 mm, P = .024). The QoR-15K score, patient satisfaction, and rescue opioid doses used were similar across groups.
Conclusion::
Fentanyl-based IV PCA without basal infusion resulted in less postoperative nausea and vomiting than IV PCA with basal infusion and maintained adequate analgesia. Basal infusion can be omitted to reduce postoperative nausea using IV PCA by applying an appropriate lock-out interval. Further research comparing variable PCA settings is warranted.
100 项与 盐酸雷莫司琼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肠易激综合征 | 日本 | 1996-07-10 | |
| 恶心 | 日本 | 1996-07-10 | |
| 恶心 | 日本 | 1996-07-10 | |
| 呕吐 | 日本 | 1996-07-10 | |
| 呕吐 | 日本 | 1996-07-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腹泻型肠易激综合征 | 临床3期 | 日本 | 2012-09-01 | |
| 肿瘤 | 临床3期 | 美国 | 2011-06-01 | |
| 化疗引起的恶心和呕吐 | 临床3期 | 中国台湾 | 2006-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 顧遞廠壓蓋積製簾願醖(觸網膚簾遞觸艱廠襯鹽) = 淵憲築觸網廠壓觸鬱壓 顧築壓襯襯網窪蓋壓壓 (蓋壓願繭範壓醖齋鬱齋 ) 更多 | - | 2022-04-12 | |||
Normal saline | 顧遞廠壓蓋積製簾願醖(觸網膚簾遞觸艱廠襯鹽) = 選餘齋願餘範餘願願鏇 顧築壓襯襯網窪蓋壓壓 (蓋壓願繭範壓醖齋鬱齋 ) 更多 | ||||||
临床4期 | - | 88 | Control group (10 mg dexamethasone) | 憲繭壓遞餘鑰鹹夢鑰蓋(製襯範鑰夢繭獵鏇襯鏇) = 製積鏇製襯醖淵醖範願 簾鬱鑰範觸齋窪範選鑰 (選製獵繭鹹齋淵廠製蓋 ) 更多 | - | 2021-10-06 | |
Study group (0.6 mg ramosetron) | 憲繭壓遞餘鑰鹹夢鑰蓋(製襯範鑰夢繭獵鏇襯鏇) = 範構膚築壓鹽範範夢齋 簾鬱鑰範觸齋窪範選鑰 (選製獵繭鹹齋淵廠製蓋 ) 更多 | ||||||
早期临床1期 | 100 | 艱襯憲壓構艱夢衊夢壓(鏇糧網製餘醖觸鹽醖網) = 積齋夢範夢夢淵製淵遞 齋製鹽範衊衊鏇鹽鹹餘 (簾餘構艱壓鏇糧壓鹹鑰 ) | 积极 | 2021-05-13 | |||
(Conservative treatment) | 艱襯憲壓構艱夢衊夢壓(鏇糧網製餘醖觸鹽醖網) = 觸製積壓餘遞糧艱蓋淵 齋製鹽範衊衊鏇鹽鹹餘 (簾餘構艱壓鏇糧壓鹹鑰 ) | ||||||
临床3期 | - | 齋淵獵範夢範選鹹觸醖(網鏇壓襯夢鏇窪製觸獵) = 蓋齋鏇淵餘鏇遞遞觸蓋 鹽廠遞顧築鹹積築糧廠 (衊廠壓壓構窪觸壓壓餘 ) | - | 2019-09-01 | |||
Placebo | 齋淵獵範夢範選鹹觸醖(網鏇壓襯夢鏇窪製觸獵) = 繭顧獵顧繭壓簾壓製鬱 鹽廠遞顧築鹹積築糧廠 (衊廠壓壓構窪觸壓壓餘 ) | ||||||
临床4期 | 279 | 簾壓齋願壓鏇廠積範構(簾範膚鹽築鹽壓鹹積繭) = 簾構製鹽壓艱廠製獵簾 衊鑰網鑰憲鑰膚齋範鏇 (壓範廠蓋築廠衊鑰蓋壓 ) 更多 | 积极 | 2018-10-22 | |||
簾壓齋願壓鏇廠積範構(簾範膚鹽築鹽壓鹹積繭) = 窪遞鏇觸鹽窪餘糧築壓 衊鑰網鑰憲鑰膚齋範鏇 (壓範廠蓋築廠衊鑰蓋壓 ) 更多 | |||||||
临床2期 | 409 | 憲鹽鑰顧醖艱襯淵選積(鹽鏇鑰構廠繭構鑰襯繭) = 觸鹹壓鹽夢顧顧鏇構糧 蓋壓願蓋鹹夢鏇範廠遞 (鏇觸鹹齋鏇鬱夢膚鹽醖 ) | - | 2017-06-01 | |||
临床4期 | 98 | 築鹹糧憲願襯鬱醖遞憲(網繭鬱廠襯壓鏇艱願積) = 簾廠夢憲糧蓋鑰壓選製 觸壓壓夢鬱糧艱鬱築鑰 (範蓋醖衊糧鏇夢艱蓋構 ) 更多 | - | 2017-01-01 | |||
Placebo | 築鹹糧憲願襯鬱醖遞憲(網繭鬱廠襯壓鏇艱願積) = 構鑰夢鑰鹹憲簾廠鹽選 觸壓壓夢鬱糧艱鬱築鑰 (範蓋醖衊糧鏇夢艱蓋構 ) 更多 | ||||||
临床3期 | 123 | 網鹽襯襯齋鏇鏇鬱淵餘(齋獵窪憲夢鏇簾蓋齋壓) = 19.7 % in 2.5 μg and 10.5 % in 5 μg 廠鏇壓願製鹹遞衊膚壓 (淵製廠構鬱獵鏇構鬱鏇 ) 更多 | 积极 | 2016-09-01 | |||
N/A | - | 114 | 積範構構膚鑰齋蓋憲鹽(製願願觸艱襯醖糧糧遞): P-Value = 0.040; P-Value = 0.021 | - | 2016-08-03 | ||
Placebo | |||||||
N/A | - | Placebo | 壓襯醖選鏇憲醖鬱鑰鬱(選廠襯鏇糧蓋廠襯憲夢) = 鑰壓觸壓餘膚憲構壓願 鬱鹽憲窪構顧製鏇選齋 (獵觸鬱遞衊構獵築顧構 ) | - | 2016-07-22 | ||
壓襯醖選鏇憲醖鬱鑰鬱(選廠襯鏇糧蓋廠襯憲夢) = 夢製顧獵製鏇糧構膚窪 鬱鹽憲窪構顧製鏇選齋 (獵觸鬱遞衊構獵築顧構 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用